Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Share-based Compensation: 2014-2024

Historic Share-based Compensation for Aclaris Therapeutics (ACRS) over the last 11 years, with Dec 2024 value amounting to $10.9 million.

  • Aclaris Therapeutics' Share-based Compensation fell 4.79% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 33.00%. This contributed to the annual value of $10.9 million for FY2024, which is 47.15% down from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Share-based Compensation is $10.9 million, which was down 47.15% from $20.5 million recorded in FY2023.
  • Over the past 5 years, Aclaris Therapeutics' Share-based Compensation peaked at $20.5 million during FY2023, and registered a low of $10.9 million during FY2024.
  • For the 3-year period, Aclaris Therapeutics' Share-based Compensation averaged around $15.5 million, with its median value being $15.0 million (2022).
  • As far as peak fluctuations go, Aclaris Therapeutics' Share-based Compensation skyrocketed by 36.59% in 2023, and later tumbled by 47.15% in 2024.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Share-based Compensation stood at $11.2 million in 2020, then increased by 25.46% to $14.1 million in 2021, then climbed by 6.96% to $15.0 million in 2022, then soared by 36.59% to $20.5 million in 2023, then crashed by 47.15% to $10.9 million in 2024.